The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other’s work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH before publication to confirm the consensus statements and recommendations. The consensus statements and recommendations presented in this report represent measures actually being conducted at the highest-level HCC treatment centers in Japan. We hope this article provides insight into the actual situation of HCC practice in Japan, thereby affecting the global practice pattern in the management of HCC.
Liver Cancer

中文翻译：

---

日本肝细胞癌的管理：JSH 共识声明和建议 2021 年更新

肝细胞癌临床实践手册是根据肝细胞癌循证临床实践指南确认的证据以及日本肝病学会 (JSH) 肝细胞癌 (HCC) 专家小组的共识意见出版的。由于 JSH 临床实践指南基于证据级别极高的原创文章，因此不包括临床实践中 HCC 管理的专家意见或新开发治疗的共识。然而，该实践手册结合了基于临床数据、专家意见和日本目前进行的真实世界临床实践的文献，以方便临床医生使用。随着 JSH 指南的每次修订，我们发布了手册更新，手册第一版于 2007 年出版，第二版于 2010 年出版，第三版于 2015 年出版，第四版于 2020 年出版，其中包括 2017 版 JSH 指南。本文摘自《HCC 临床实践手册》第四版，重点介绍 HCC 的病理学、诊断和治疗。它被设计为与最新版本的 JSH 临床实践指南不同的实用手册。本实践手册由 JSH 的专家小组编写，重点介绍了 JSH 专家小组提出的 HCC 管理的共识声明和建议。在这篇文章中，我们包括了在该领域的日本专家中相对常见的新开发的临床实践，尽管他们的所有陈述都没有与高水平的证据相关联，但这些做法很可能在未来被纳入指南。为撰写本文，来自不同机构的合著者起草了内容，然后批判性地审查了彼此的工作。修订后的内容在发布前由 JSH 董事会和规划与公共关系委员会进行了严格审查，以确认共识声明和建议。本报告中提出的共识声明和建议代表了日本最高级别的 HCC 治疗中心实际采取的措施。我们希望本文能够深入了解日本 HCC 实践的实际情况，从而影响 HCC 管理的全球实践模式。来自不同机构的合著者起草了内容，然后批判性地审查了彼此的工作。修订后的内容在发布前由 JSH 董事会和规划与公共关系委员会进行了严格审查，以确认共识声明和建议。本报告中提出的共识声明和建议代表了日本最高级别的 HCC 治疗中心实际采取的措施。我们希望本文能够深入了解日本 HCC 实践的实际情况，从而影响 HCC 管理的全球实践模式。来自不同机构的合著者起草了内容，然后批判性地审查了彼此的工作。修订后的内容在发布前由 JSH 董事会和规划与公共关系委员会进行了严格审查，以确认共识声明和建议。本报告中提出的共识声明和建议代表了日本最高级别的 HCC 治疗中心实际采取的措施。我们希望本文能够深入了解日本 HCC 实践的实际情况，从而影响 HCC 管理的全球实践模式。修订后的内容在发布前由 JSH 董事会和规划与公共关系委员会进行了严格审查，以确认共识声明和建议。本报告中提出的共识声明和建议代表了日本最高级别的 HCC 治疗中心实际采取的措施。我们希望本文能够深入了解日本 HCC 实践的实际情况，从而影响 HCC 管理的全球实践模式。修订后的内容在发布前由 JSH 董事会和规划与公共关系委员会进行了严格审查，以确认共识声明和建议。本报告中提出的共识声明和建议代表了日本最高级别的 HCC 治疗中心实际采取的措施。我们希望本文能够深入了解日本 HCC 实践的实际情况，从而影响 HCC 管理的全球实践模式。
肝癌